AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

A new study published in the journal of Movement Disorders showed that Parkinson's disease (PD) was found to be independently ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...